Insulin Detemir Results in Less Weight Gain than NPH Insulin When Used in Basal-Bolus Therapy for Type 2 Diabetes Mellitus, and this Advantage Increases with Baseline Body Mass Index

Author： Rašlová Katarina  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.27, Iss.4, 2007-01, pp. : 279-285

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Observational 6-month Open-label Study of Japanese Type 2 Diabetes Patients Switching from NPH Insulin to Insulin Detemir in Basal–Bolus Regimen: 23rd Article of the Japan Diabetes Clinical Data Management Study Group (JDDM23)

By Oishi M   Abe N   Yokoyama H   Kuribayashi N   Tomonaga O   Matoba K   Kobayashi M  

The Journal of International Medical Research, Vol. 40, Iss. 2, 2012-03 ,pp. : 787-797

Field House Publishing

Access to resources Recommend Favorite

Basal-bolus insulin superior to sliding scale insulin in T2DM

By  

Inpharma, Vol. 1, Iss. 1612, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Insulin: basal-bolus more cost effective than premixed for T2DM

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 634, 2011-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 21, Iss. 9, 2005-09 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Defining the Role of Insulin Detemir in Basal Insulin Therapy

By Morales Javier  

Drugs, Vol. 67, Iss. 17, 2007-01 ,pp. : 2557-2584

Adis International

Access to resources Recommend Favorite